DNA Damage Response Targeting Therapeutics (Beyond PARP Inhibitors) - Current Market Landscape


DNA damage can be referred to as any adverse alteration, which may occur in the form of base additions, base deletions or break in the sister DNA strands. During our research, we came across over 43 companies that are presently engaged in the development of DDR targeting therapeutics.

.

There has been a significant increase in the number of developers that have been established in this domain post-2008. In fact, close to XX players were established during the period 2013-2016. Further, over XX developers have been founded since 2017.  In higher eukaryotes, various DNA repair mechanism are involved in the repair of the specific damage caused by both, exogenous and endogenous factors. Further, they also possess an elaborate and highly coordinated DNA damage response (DDR) system.

 

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market/request-sample.html

One of the key objectives of the report was to estimate the existing market size and future opportunity for DNA targeting therapeutics developers, over the next decade. 

 

The market is characterized by the presence of large companies (more than 500 employees), mid-sized players (51-500 employees), small companies (11-50 employees) and very small companies (2-10 employees). It is worth mentioning that small companies are pre-dominantly contributing to this field (XX%). Notably, the industry has also witnessed contributions from several large firms (XX%). such as (in alphabetical order) XX, AstraZeneca, XX, Bristol Myers Squibb, XX, XX and Vertex Pharmaceuticals.

 

In North America, the US (XX) emerged as the most prominent region wherein majority of the DDR targeting therapeutics developers are located, followed by Canada (XX). While most of the developers are based in UK (XX) in Europe, maximum number of players are headquartered in Australia and Japan (XX each) within the Asia-Pacific region. XX emerged as the leading developer in this domain, having the maximum (XX) number of DDR targeting therapeutics in its current pipeline. Most (XX) of the drug candidates of the aforementioned firm are currently in preclinical stages. This is followed by XX, XX, XX, XX, Senhwa Biosciences and XPose Therapeutics, having XX drug candidates, each.

 

Majority (XX%) of the clinical stage DDR targeting therapies are being evaluated in phase I trials, followed by those currently in phase II (XX%) and phase I / II (XX%) studies. Further, majority (XX%) of the preclinical drug candidates are in preclinical (unspecified) stages, followed by those in discovery (25%) and lead optimization (XX%) stages. Notably, majority of the clinical DDR targeting therapeutics are being developed to target ATR (XX%), followed by those designed for WEE1 (8%) molecules. DNA-PK, p53, RNA polymerase I and APE1/Ref-1 are other popular target molecules for clinical stage candidates.

 

DNA Damage Repair (DDR): This system involves a coordinated sequence of events, involving the detection of DNA damage points (by sensor proteins), followed by the transduction of information ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) and the subsequent repair of damaged DNA segments.

 

 

 

It is worth mentioning that majority (XX) of the clinical stage drug candidates target solid tumors, followed by those being developed for the treatment of leukemia (XX) and myelodysplastic syndrome (XX). Examples of therapies targeting myelodysplastic syndrome include (in reverse order of phase of development) XX (phase III), XX (phase II), and XX (phase II), XX (phase I), XX (phase I) and XX (phase I).

 

Further, majority (XX) of the preclinical stage DDR targeting therapies are being developed for cancer (unspecified), followed by those intended for the treatment of solid tumors (unspecified) (XX). In recent years, players from across the globe have initiated research to evaluate the therapeutic potential of DDR targeting drug candidates against non-oncological indications, including Alzheimer’s disease and Parkinson’s disease.

 

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

  1. Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
  2. DNA-Encoded Libraries: Platforms and Services Market
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030

 

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

 

Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

 

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/

Comments